Particle.news
Download on the App Store
9 ARTICLES
·
last wk.

AstraZeneca Pledges $50 Billion to Expand U.S. Drug Manufacturing

AstraZeneca aims to secure U.S. supply chains by shifting manufacturing to domestic facilities in response to looming tariffs.

A sign is pictured during the unveiling of AstraZeneca's new manufacturing facility, to be operational in the coming months with an initial focus on T-cell therapies, in Rockville, Maryland, U.S., May 5, 2025. REUTERS/Jonathan Ernst/File Photo
Image
Image
Image

Overview

  • New funds will build a drug manufacturing plant in Virginia and expand R&D and cell therapy facilities in Maryland, Massachusetts, California, Indiana and Texas.
  • AstraZeneca tied the investment to President Trump’s threatened import levies and an ongoing Commerce Department probe into pharmaceutical imports.
  • The company said the commitment underpins its goal of reaching $80 billion in annual revenue by 2030 with half derived from U.S. sales.
  • Executives expect the expansion to create tens of thousands of skilled U.S. jobs, though they declined to provide precise projections.
  • The pledge builds on a $3.5 billion U.S. investment from November 2024 and matches a similar $50 billion plan by Roche while outstripping rival spending commitments.